Vernalis Share Discussion Threads

[master rsi] 02/11/2006 09:00

Next week CEO gives an overview of the company.......

2 November 2006

Vernalis to Present at Cowen and Company
7th Annual Global Health Care Conference

WINNERSH, U.K., November 2, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), a
specialty bio-pharmaceutical and drug development company, today announced that
Simon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer,
will participate in the Cowen and Company 7th Annual Global Health Care
Conference to be held November 7-8, 2006 at the Landmark Hotel in London. Mr.
Sturge is scheduled to present an overview of the Company's business activities
and product pipeline at 16:50 GMT on Wednesday, November 8, 2006.

Investors may access a live webcast of the presentation at www.vernalis.com
under the Investor Relations tab. The presentation will be archived for 3
months.

[fhmktg] 30/10/2006 12:34

Bring 'em on!!!

Website shows:

H2/06

-V1512 Start of Phse II for Parkinson
-V2006 start Phase II for Parkinsons, with Milestone due from Biogen
- V24343 Start of Phase I for obesity-Hsp90 Start of Phase I candidate by Novartis, with milestone payment to Vernalis
- V10153 recruitment of paterients for Phase IIa for stroke

19th May 2007 end of review by FDA for use of Frova in menstrual migraine; if successful leads to $40 million payment by Endo.

Will be interested in seeing update on sales of Frova in Europe, which stated in H1

[rhtshah2] 30/10/2006 12:28

Fall due to boredom I guess but have a look at this, which is from the recently announced interims...."the second half of 2006 is expected to have substantial news flow as the group progresses its drug candidates through the clinic and boosts product revenues." So I think it was deliberately brought down by the mm's as some important news is imminent.

[latifs100] 27/10/2006 15:18

all gains lost in a week..from 70p back to 60p.. betta to be in antisoma

[adgd2] 27/10/2006 14:03

me too @79p. i get the feeling this is going nowhere fast.

[latifs100] 27/10/2006 13:40

another dog in portfolio,,bot at 86p

[adgd2] 29/9/2006 14:21

probably 'cos some pretty big trades going through

[wikroberts] 29/9/2006 14:16

Why the sudden rise ?

[maysun] 23/9/2006 09:31

Hello guys,

How are we doing here?

Looking bloody good to me!!!!!!!

LOL!!!

[adgd2] 22/9/2006 11:59

Anyone got any idea what is happening today? Weeks of nothing, and now 9m traded.
(also 1 bought at £1 - what?!?!?!)

[fickena] 22/9/2006 10:35

Oh hello,

Something definitely afoot here today. 4.6m traded before midday?

[rhtshah2] 20/9/2006 12:19

UBS Global Life Sciences Conf

RNS Number:2207J
Vernalis PLC
20 September 2006




20 September 2006

Vernalis plc to Present at UBS Global Life Sciences Conference on September 26,
2006


WINNERSH, U.K., September 20, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), a
specialty bio-pharmaceutical and drug development company, today announced that
Simon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer,
will participate in the UBS Global Life Sciences Conference to be held September
25-28, 2006 at the Grand Hyatt in New York City. Mr. Sturge is scheduled to
present an overview of the Company's business activities and product pipeline at
8:00 AM Eastern time on Tuesday, September 26, 2006.

To listen to the audio webcast of the presentation, please visit:
www.ibb.ubs.com

[rhtshah2] 13/9/2006 09:02

Vernalis - sit tight says today's Daily Mail.

[fickena] 13/9/2006 07:41

Yep! Finally looking up for us;

Vernalis points to positive newsflow
Tue 12 Sep 2006

VER - Vernalis

LONDON (SHARECAST) - Biotech Vernalis narrowed losses modestly over the first half said it expects a stream of positive newsflow during the second half.

Chief executive Simon Sturge said, "The second half of 2006 is expected to have substantial news flow as we progress our drug candidates through the clinic and boost our product revenues."

Vernalis completed final Phase III study in May in order to gain approval for Frova to be used as an intermittent, short-term preventative treatment for menstrual migraine.

The group said it has now submitted its supplemental new drug application with the US Food and Drug Administration and if successful hopes to gain approval by mid-2007.

Vernalis said pre-tax losses narrowed slightly to £19.4m for the six months to June from a loss of £20.0m a year ago, while revenues increased to £6.6m against £5.9m last time.

The group has a strong cash pile following a successful fund raising completed at the end of 2005, with cash as of the end of June totalling £50.9m.

[fhmktg] 13/9/2006 07:29

Thats the kind of RNS I like -three directors, including Dr F buying shares!
Presumably theses are not part of an incentive scheme, but on their own accounts?

13/09/06 07:04 UKREG Director/PDMR Shareholding

[kmjs] 12/9/2006 11:54

The above post was infact edited to "I believe" the opportunistic take over
in 2005 was from Vernalis, at about 28p, and "no wonder they would want OXB".

The post was part of an exchange on the likelyhood of counter take over
attempts for OXB if a bidder appears.

Prosavin has been touted as a "cure" for Parkinson's, but has not as yet
started trials. If it turns out to be as good as claimed, then IMHO it will
become the treatment of choice.

Prior to that, it could just as easily be overtaken by some new "find".

DYOR

[fickena] 12/9/2006 08:52

Vernalis H1 pretax loss narrows

LONDON (AFX) - Vernalis PLC reported narrowing losses in the first half of
2006 and said it sees a busy period of clinical development ahead.
Pretax loss for the six months to end-June was 19.4 mln stg compared with a
loss of 20.0 mln the previous year.
Vernalis said its financial position is strong with closing cash of 50.9 mln
stg at the end of the half.
Chief executive officer Simon Sturge said Vernalis is continuing to show
substantial progress toward becoming a self-funding, sustainable R&D driven
commercial business.
In the first half, establishing the US operation with the successful launch
of Apokyn and completing the Frova clinical trials for the short-term prevention
of menstrual migraine were significant achievements, he said.
And he added that the second half of 2006 is expected to have substantial
news flow as the group progresses its drug candidates through the clinic and
boosts product revenues.
[e-mail]
slm

[maysun] 12/9/2006 07:44

Slowly and steadily, the company business fundamental is strenghtening, the process will continue and accelerate. Cash remains strong, exciting news expected in next 3 months, milestone payments starts to flow in.
Todays result will not push up SP, creating a window opportunity for the well reseached investors weeks to aquire more shares on weakness - definately one to accumulate for a profitable 2007...........LOL!!!!
Won't surprise me the company is sold for a high premium during 2008.........LOL!!!!

[fhmktg] 07/9/2006 19:09

Good, IMHO; lets get the US approval of Frova for menstrual migraine plus update on trials and I expect (hope?) that Dr Fellner will have an acquisition or merger in his back pocket, once the future looks secured.

[robin_of_loxley] 07/9/2006 01:06

hmm not much excitement here then at the moment....

[rovi57] 06/9/2006 10:30

good post. although they dont seem to be able to attract the buyers, bought in at 67.3 so holiday fund could do with this one jumping.

[rhtshah2] 05/9/2006 14:38

Really surprised to see share price at this low level and lack of interest in this share when the interim results is just round the corner (12th Sept). One of the weekend papers tipped it as a buy about two/three months back when the share price was around 75p. Below is the outlook statement issued by the company in their last result announcement.


Outlook for 2006

Income is expected to increase in 2006 as a full year of sales from Apokyn(R) in
North America will be recognised compared with two months in 2005. In addition,
revenues from frovatriptan in Europe are expected to show a small increase. Endo
will make a contractual anniversary payment of $15.0 million to Vernalis in
September 2006 (as in September 2005) in respect of Frova(R) in North America
with a variable royalty based on sales commencing on 1 January 2007. Recurring
revenues, representing release of deferred income from licensing agreements
entered into prior to 31 December 2005 are expected to be approximately #5.1
million. This is a non-cash item and includes recognition of a proportion of the
$15 million payment from Endo. Additional revenues may arise on achievement of
milestones in existing collaborations or any further licensing agreements